Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed) (PAR-23-211)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging

Due Date: October 04, 2023.

Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD and other ADRDs (R01 - Clinical Trial Not Allowed) (PAR-23-212)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging

Due Date: October 04, 2023

Chan Zuckerberg Initiative

Sponsor: Chan Zuckerberg Initiative

Due Date: Applications due July 11, 2023, by 5 p.m. Pacific Time

Assessment of TBI-related ADRD Pathology Related to Cognitive Impairment and Dementia Outcomes (U01 - Clinical Trial Not Allowed) (RFA-NS-24-003)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging

Due Date: July 28, 2023.

Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed) (RFA-NS-24-010)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging

Due Date: LOI due August 8, 2023. Application due September 08, 2023.

Understanding Gene-Environment Interactions in Brain Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Not Allowed) (RFA-AG-24-021)

Sponsor: National Institute on Aging

Due Date: LOI due September 22, 2023. Application due October 23, 2023.

Quantifying the Impact of Environmental Toxicants on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Risk in Cohort Studies (U01 Clinical Trial Not Allowed) (RFA-AG-24-022)

Sponsor: National Institute on Aging

Due Date: LOI due September 22, 2023. Application due October 23, 2023.

Preclinical Studies to Characterize the Impact of Toxicants on Brain Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Not Allowed) (RFA-AG-24-023)

Sponsor: National Institute on Aging

Due Date: LOI due September 22, 2023. Application due October 23, 2023.

Measuring Financial Hardship Among People and Families Living with AD/ADRD (R01 Clinical Trial Not Allowed)? (RFA-AG-24-036)

Sponsor: National Institute on Aging

Due Date: LOI due September 23, 2023. Application due October 23, 2023.

Significance of Clonal Hematopoiesis (CH) in Aging Humans (R01 Clinical Trial Not Allowed)? (RFA-AG-24-038)

Sponsor: National Institute on Aging

Due Date: LOI due September 23, 2023. Application due October 23, 2023.

Collaborative Opportunities for Multidisciplinary, Bold, and Innovative Neuroscience (COMBINE) (RM1 Clinical Trial Optional) (RFA-NS-23-027)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional) (RFA-MH-23-295)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Predoctoral to Postdoctoral Transition Award (F99/K00 Clinical Trial Not Allowed) (RFA-OD-23-016)

Sponsor: National Institutes of Health

Due Date: July 01, 2023.

NINDS Postdoctoral Mentored Career Development Award (K01 Clinical Trial Required) (PAR-23-142)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

NINDS Postdoctoral Mentored Career Development Award (K01 No Independent Clinical Trial Allowed) (PAR-23-143)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.